Dr. Block is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dana-Farber Cancer Center
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3800
Summary
- Dr. Caroline Block is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. She received her medical degree from University of Michigan Medical School and has been in practice 32 years. She specializes in breast cancer.
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1988 - 1990
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1985 - 1988
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1987
- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1985 - 1986
- University of Michigan Medical SchoolClass of 1985
Certifications & Licensure
- MA State Medical License 1987 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2009 Jun 01
- Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsPACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Horm...Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma
Journal of Clinical Oncology. 2024-06-10 - 9 citationsAvoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective StudyInes Vaz-Luis, Romualdo Barroso-Sousa, Antonio Di Meglio, Jiani Hu, Rebecca Rees
Journal of Clinical Oncology. 2020-04-24 - 5 citationsCharacteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC programRandie E White, Laura E.G. Warren, Faina Nakhlis, Jennifer M. Rosenbluth, Jennifer R. Bellon
The Breast Journal. 2020-09-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: